Cited by 277HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>

Staszewski, Schlomo·2001·JAMA

Open this paper in CoChat — free account

Abstract

Context Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment. Objective To evaluate antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine regimen compared with an indinavir-lamivudine-zidovudine regimen. Design and setting A multicenter, phase 3, randomized, double-blind trial with an enrollment period from August 1997 to June 1998, with follow-up through 48 weeks at 73 clinical research units in the United States, Canada, Australia, and Europe. Patients Five hundred sixty-two antiretroviral-naive, HIV-infected adults with a plasma HIV RNA level of at least 10 000 copies/mL and a CD4 cell count of at least 100 x 10(6)/L. Interventions Patients were stratified by baseline HIV RNA level and randomly assigned to receive a combination tablet containing 150 mg of lamivudine and 300 mg of zidovudine twice daily plus either 300 mg of abacavir twice daily and indinavir placebo or 800 mg of indinavir every 8 hours daily plus abacavir placebo. After 16 weeks, patients with confirmed HIV RNA levels greater than 400 copies/mL were eligible to continue receiving randomized treatment or receive open-label therapy. Main outcome measure Virologic suppression, defined as HIV RNA concentration o…

Integrity signals

Registry

Crossref · 10.1001/jama.285.9.1155

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,197
1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
Castro, K. G., Ward, J., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,347
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Hammer, S. M., Squires, K., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J., Balfour, H. H., Deyton, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,638
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
Gulick, R. M., Mellors, J. W., Havlir, D. V., Eron, J. J., Gonzalez, C. J., McMahon, D. K., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,883
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,090
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065
Antiretroviral Therapy in Adults
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B., Hammer, S. M., Hirsch, M., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,007
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Self-citation
1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
(1993) · JAMA · doi:10.1001/jama.1993.03500040022009 · Cited by 964

Flagged first, then by citations

Show all 38 references

Sorted by citations

Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT 2010 Statement
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S. A., Phillips, E. J., Carosi, G., Molina, J., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugină, S., Козырев, О. А., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,834
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,090
Treatment for Adult HIV Infection
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M., Carpenter, C. C. J., Fischl, M. A., Gazzard, B., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,034
Treatment for Adult HIV Infection
Yéni, P., Hammer, S. M., Hirsch, M., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 780
Understanding Equivalence and Noninferiority Testing
Walker, E., & Nowacki, A. S. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1513-8 · Cited by 751
Antiretroviral Treatment for Adult HIV Infection in 2002
Yéni, P., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B., Hirsch, M., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 710
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S. L., Bernstein, B. M., King, M. S., Arribas, J. R., Beall, G. N., Ruane, P. J., Johnson, M. A., Johnson, D., LALONDE, R. G., Japour, A. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 646
Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach
Curran, J. W., Debas, H. T., Arya, M., Kelley, P., Knobler, S., & Pray, L. A. (2005) · Cited by 534
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 521
Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana
Shapiro, R., Hughes, M. D., Ogwu, A., Kitch, D. W., Lockman, S., Moffat, C., Makhema, J. M., Moyo, S. M., Thior, I., McIntosh, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907736 · Cited by 519
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*
Dybul, M. R., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients
Saag, M. S., Balu, R. B., Phillips, E. J., Brachman, P. S., Martorell, C. T., Burman, W. J., Stancil, B. S., Mosteller, M., Brothers, C. H., Wannamaker, P. G., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529382 · Cited by 427
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
Hetherington, S., McGuirk, S., Powell, G., Cutrell, A. G., Naderer, O. J., Spreen, B., Lafon, S., Pearce, G., & Steel, H. M. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 407
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
Bartlett, J. A., DeMasi, R. A., Quinn, J., Moxham, C. P., & Rousseau, F. S. (2001) · AIDS · doi:10.1097/00002030-200107270-00006 · Cited by 384
Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy
Wit, F. W. N. M., Weverling, G. J., Weel, J. F. L., Jurriaans, S., & Lange, J. M. A. (2002) · The Journal of Infectious Diseases · doi:10.1086/341084 · Cited by 314
Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published Literature
Ivers, L. C., Kendrick, D. C., & Doucette, K. E. (2005) · Clinical Infectious Diseases · doi:10.1086/431199 · Cited by 313
Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K. R., Peeples, L., Godfrey, C. C., Jahed, N. C., Myers, L., Katzenstein, D. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906768 · Cited by 312
Addressing the Challenges of Adherence
Bartlett, J. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200202011-00002 · Cited by 307
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
Martínez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021589 · Cited by 291
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K., & Pirmohamed, M. (2004) · Pharmacogenetics · doi:10.1097/00008571-200406000-00002 · Cited by 291
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
Bartlett, J. A., Fath, M. J., DeMasi, R. A., Hermes, A., Quinn, J., Mondou, E., & Rousseau, F. S. (2006) · AIDS · doi:10.1097/01.aids.0000247578.08449.ff · Cited by 242
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210
Efficacy of highly active antiretroviral therapy in HIV-1 infected children
van Rossum, A. M. C., Fraaij, P. L., & de Groot, R. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00183-4 · Cited by 182
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
van Leeuwen, R., Katlama, C., Murphy, R. L., Squires, K., Gatell, J. M., Horban, A., Clotet, B., Staszewski, S., van Eeden, A., Clumeck, N., et al. (2003) · AIDS · doi:10.1097/00002030-200305020-00007 · Cited by 170
Self-citation
Abacavir use and cardiovascular disease events
Cruciani, M., Zanichelli, V., Serpelloni, G., Bosco, O., Malena, M., Mazzi, R., Mengoli, C., Parisi, S. G., & Moyle, G. J. (2011) · AIDS · doi:10.1097/qad.0b013e328349c6ee · Cited by 154
A Review of the Pharmacokinetics of Abacavir
Yuen, G. J., Weller, S., & Pakes, G. E. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847060-00001 · Cited by 152
Abacavir Hypersensitivity Reaction
Hewitt, R. G. (2002) · Clinical Infectious Diseases · doi:10.1086/339751 · Cited by 149
Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects
Gallant, J. E., Rodriguez, A. E., Weinberg, W. G., Young, B., Berger, D. S., Lim, M. L., Liao, Q., Ross, L., Johnson, J., Shaefer, M. S., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/498069 · Cited by 147
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
Clumeck, N., Goebel, F. D., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., Johnson, M. A., Gazzard, B., Stone, C., Athisegaran, R., et al. (2001) · AIDS · doi:10.1097/00002030-200108170-00009 · Cited by 144
Self-citation
Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte dʼIvoire
Djomand, G., Roels, T. H., Ellerbrock, T. V., Hanson, D. L., Diomandé, F. V. K., Monga, B., Maurice, C., Nkengasong, J. N., Konan-Koko, R., Kadio, A., et al. (2003) · AIDS · doi:10.1097/00002030-200317003-00002 · Cited by 139
A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection
Opravil, M., Hirschel, B. J., Lazzarin, A., Furrer, H., Chave, J., Yerly, S., Bisset, L. R., Fischer, M., Vernazza, P., Bernasconi, E., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/340312 · Cited by 134
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa
DART Virology Group and Trial Team (2006) · AIDS · doi:10.1097/01.aids.0000233572.59522.45 · Cited by 129
Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial
Eron, J. J., Feinberg, J., Kessler, H. A., Horowitz, H. W., Witt, M. D., Carpio, F., Wheeler, D. A., Ruane, P. J., Mildvan, D., Yangco, B. G., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/380799 · Cited by 122
Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización febrero de 2009)
de Gesida, P. D. E., & el Sida, P. N. S. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2008.11.002 · Cited by 121
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l
Opravil, M., Ledergerber, B., Furrer, H., Hirschel, B. J., Imhof, A., Gallant, S., Wagels, T., Bernasconi, E., Meienberg, F., Rickenbach, M., et al. (2002) · AIDS · doi:10.1097/00002030-200207050-00009 · Cited by 111
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
Quercia, R., Perno, C. F., Koteff, J. A., Moore, K. H. P., McCoig, C. C., Clair, M. S., & Kuritzkes, D. R. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001660 · Cited by 107
Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010)
de Gesida, P. D. E., & el Sida, P. N. S. (2010) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2010.03.002 · Cited by 99
Current status of antiretroviral therapy
Temesgen, Z., Warnke, D., & Kasten, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1541 · Cited by 93
Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency
McGuigan, C., Harris, S., Daluge, S. M., Gudmundsson, K. S., McLean, E. W., Burnette, T. C., Marr, H. B., Hazen, R. J., Condreay, L. D., Johnson, L. C., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0491400 · Cited by 93
Hyperlactataemia syndromes associated with HIV therapy
Ogedegbe, A., Thomas, D. L., & Diehl, A. M. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00654-6 · Cited by 90
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility
Hughes, A. R., Spreen, W. R., Mosteller, M., Warren, L. L., Lai, E., Brothers, C. H., Cox, C. J., Nelsen, A. J., Hughes, S., Thorborn, D. E., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.3 · Cited by 89
Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily
Yuen, G. J., Lou, Y., Bumgarner, N. F., Bishop, J. P., Smith, G. A., Otto, V. R., & Hoelscher, D. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.176-182.2004 · Cited by 85
TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results
Katlama, C., Fenske, S. W., Gazzard, B., Lazzarin, A., Clumeck, N., Mallolas, J., Lafeuillade, A., Mamet, J.-P., & Beauvais, L. (2003) · HIV Medicine · doi:10.1046/j.1468-1293.2003.00139.x · Cited by 84
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine
Gerstoft, J., Kirk, O., Obel, N., Pedersen, C., Mathiesen, L., Nielsen, H. I., Katzenstein, T. L., & Lundgren, J. D. (2003) · AIDS · doi:10.1097/00002030-200309260-00005 · Cited by 79
Scientific and Ethical Issues in Equivalence Trials
Djulbegović, B. (2001) · JAMA · doi:10.1001/jama.285.9.1206 · Cited by 79
Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected Patients
Khanlou, H., Yeh, V., Guyer, B., & Farthing, C. (2005) · AIDS Patient Care and STDs · doi:10.1089/apc.2005.19.135 · Cited by 77
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007)
Aldeguer, J. L. (2007) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13096750 · Cited by 76
A Randomized Trial of 2 Different 4‐Drug Antiretroviral Regimens versus a 3‐Drug Regimen, in Advanced Human Immunodeficiency Virus Disease
Fischl, M. A., Ribaudo, H. J., Collier, A. C., Erice, A., Giuliano, M., Dehlinger, M., Eron, J. J., Saag, M. S., Hammer, S. M., Vella, S., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377311 · Cited by 75
Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine
Bartlett, J. A., Johnson, J., Herrera, G., Sosa, N. R., Rodriguez, A., Liao, Q., Griffith, S. K., Irlbeck, D. M., & Shaefer, M. S. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000243092.40490.26 · Cited by 74
Response to Lamivudine-Zidovudine plus Abacavir Twice Daily in Antiretroviral-Naive, Incarcerated Patients with HIV Infection Taking Directly Observed Treatment
Kirkland, L. R., Fischl, M. A., Tashima, K. T., Paar, D. P., Gensler, T., Graham, N. M. H., Gao, H., Rosenzweig, J. R. C., McClernon, D. R., Pittman, G. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/338400 · Cited by 74
Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients
Rawlings, M. K., Thompson, M., Farthing, C., Brown, L. S., Racine, J., Scott, R. C., Crawford, K. H., Goodwin, S., Tolson, J. M., Williams, V. C., et al. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200310010-00007 · Cited by 72
A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity
Kumar, P. N., Rodriguez‐French, A., Thompson, M., Tashima, K. T., Averitt, D., Wannamaker, P. G., Williams, V. C., Shaefer, M. S., Pakes, G. E., Pappa, K. A., et al. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00346.x · Cited by 69
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine
Gulick, R. M., Meibohm, A. R., Havlir, D. V., Eron, J. J., Mosley, A., Chodakewitz, J., Isaacs, R., Gonzalez, C. J., McMahon, D. K., Richman, D. D., et al. (2003) · AIDS · doi:10.1097/00002030-200311070-00009 · Cited by 68
K65R with and without S68: A New Resistance Profile in Vivo Detected in Most Patients Failing Abacavir, Didanosine and Stavudine
Røge, B. T., Katzenstein, T. L., Obel, N., Nielsen, H. I., Kirk, O., Pedersen, C., Mathiesen, L., Lundgren, J. D., & Gerstoft, J. (2003) · Antiviral Therapy · doi:10.1177/135965350300800212 · Cited by 67
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients
Gallant, J. E., Staszewski, S., Pozniak, A., DeJesus, E., Suleiman, J. M. A. H., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., & Cheng, A. (2004) · Cited by 62
Self-citation
Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives
McGuigan, C., Hassan-Abdallah, A., Srinivasan, S., Wang, Y., Siddiqui, A. Q., Daluge, S. M., Gudmundsson, K. S., Zhou, H., McLean, E. W., Peckham, J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060776w · Cited by 61
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)
Saag, M. S., Tebas, P., Sension, M., Conant, M. A., Myers, R. E., Chapman, S. K., & Anderson, R. (2001) · AIDS · doi:10.1097/00002030-200110190-00009 · Cited by 61
Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy
Bartlett, J. A., Buda, J. J., von Scheele, B., Mauskopf, J., Davis, E. A., Elston, R., King, M. S., & Lanier, E. R. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000197070.69859.f3 · Cited by 61
Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing
Zhou, Y., Krebs, K., Milani, L. A., & Lauschke, V. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1944 · Cited by 60
Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies
Tonk, E. C. M., Gurwitz, D., der Zee, A. H. M., & Janssens, A. C. J. W. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.34 · Cited by 58
Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients
van der Ende, M. E., Prins, J. M., Brinkman, K., Keuter, M., Veenstra, J., Danner, S. A., Niesters, H. G. M., Osterhaus, A. D. M. E., & Schutten, M. (2003) · AIDS · doi:10.1097/00002030-200317003-00008 · Cited by 57
Pneumocystis carinii Pneumonia in HIV-Infected Patients in the HAART Era
Pulvirenti, J., Herrera, P., Venkataraman, P., & Ahmed, N. (2003) · AIDS Patient Care and STDs · doi:10.1089/108729103322108139 · Cited by 57
European guidelines for the clinical management and treatment of HIV-infected adults in Europe
Clumeck, N., Wit, S. D., Hermans, P., Colebunders, R., Reiss, P., Sönnerborg, A. B., Soriano, V., Vandamme, A., & Youle, M. S. (2003) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.1097/01.aids.0000060397.18106.12 · Cited by 55
Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine‐Lamivudine plus Nevirapine and Zidovudine‐Lamivudine plus Abacavir
Ndembi, N., Goodall, R. L., Dunn, D. T., McCormick, A., Burke, A., Lyagoba, F., Munderi, P., Katundu, P., Kityo, C. M., Robertson, V., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/648590 · Cited by 54
PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events
Hughes, S. H., Hughes, A. R., Brothers, C. H., Spreen, W. R., & Thorborn, D. E. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.286 · Cited by 53
Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review
Chowers, M., Gottesman, B. S., Leibovici, L., Pielmeier, U., Andreassen, S., & Paul, M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp191 · Cited by 53
Antiretroviral-associated liver injury
Ogedegbe, A., & Sulkowski, M. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00023-0 · Cited by 53
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002
Rubio, R., Berenguer, J., Miró, J. M., Antela, A., Iribarren, J. A., González, J., Guerra, L., Moreno, S., Arrizabalaga, J., Clotet, B., et al. (2002) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(02)72804-8 · Cited by 53
A review of drug patch testing and implications for HIV clinicians
Shear, N. H., Milpied, B., Bruynzeel, D. P., & Phillips, E. J. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb60 · Cited by 51
Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial
Matheron, S., Descamps, D., Boué, F., Livrozet, J., Lafeuillade, A., Aquilina, C., Troisvallets, D., Goetschel, A., Brun‐Vézinet, F., Mamet, J.-P., et al. (2003) · Antiviral Therapy · doi:10.1177/135965350300800211 · Cited by 50
Active-control equivalence trials and antihypertensive agents
McAlister, F. A., & Sackett, D. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00900-7 · Cited by 49
Designing and interpreting HIV noninferiority trials in naive and experienced patients
Hill, A. M., & Sabin, C. A. (2008) · AIDS · doi:10.1097/qad.0b013e3282f5556d · Cited by 46
Improving the information content of categorical clinical trial endpoints
Berger, V. W. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00233-7 · Cited by 46
Predictive Value of Provirus Load and DNA Human Immunodeficiency Virus Genotype for Successful Abacavir‐Based Simplified Therapy
Pellegrin, I., Caumont‐Sarcos, A., Garrigue, I., Merel, P., Schrive, M., Fleury, H. J., Dupon, M., Pellegrin, J., & Ragnaud, J. (2002) · The Journal of Infectious Diseases · doi:10.1086/345860 · Cited by 45
European guidelines for the clinical management and treatment of HIV-infected adults in Europe
The EACS Euroguidelines Group (2003) · AIDS · doi:10.1097/00002030-200306002-00002 · Cited by 45
HIV Medicine 2005
Hoffmann, C., Jk, R., & Kamps, B. S. (2005) · Cited by 45
Backs against the Wall: Novel and Existing Strategies Used during the 2014-2015 Ebola Virus Outbreak
Wong, G., & Kobinger, G. P. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-15 · Cited by 43
Simultaneous quantification of a non‐nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry
Nirogi, R. V. S., Bhyrapuneni, G., Kandikere, V. N., Mudigonda, K., Komarneni, P., Aleti, R. R., & Mukkanti, K. (2008) · Biomedical Chromatography · doi:10.1002/bmc.1125 · Cited by 43
γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial
Won, J. C., Kwon, H., Moon, S., Chun, S. W., Kim, C. H., Park, I. B., Kim, I. J., Lee, J., Cha, B. Y., & Park, T. S. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0099 · Cited by 46
Fractionated Neem Leaf Extract is Safe and Increases CD4+ Cell Levels in HIV/AIDS Patients
Mbah, A. U., Udeinya, I. J., Shu, E. N., Chijioke, C. P., Nubila, T., Udeinya, F., Muobuike, A., Mmuobieri, A., & Obioma, M. S. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180a72199 · Cited by 42
Tuberculosis and HIV: A Partnership Against the Most Vulnerable
Cahn, P. E., Pérez, H., Ben, G., & Ochoa, C. (2003) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/154510970300200303 · Cited by 42
HIV therapy in 2003
Volberding, P. A. (2003) · AIDS · doi:10.1097/00002030-200304001-00002 · Cited by 42
Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)
Vibhagool, A., Cahn, P. E., Schechter, M., Smaill, F., Soto-Ramírez, L. E., Carosi, G., Montroni, M., Pharo, C. E., Jordan, J. C., Thomas, N. E., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004006 · Cited by 41
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine
Wit, F. W. N. M., Wood, R., Horban, A., Beniowski, M., Schmidt, R. E., Gray, G., Lazzarin, A., Lafeuillade, A., Paes, D., Carlier, H., et al. (2001) · AIDS · doi:10.1097/00002030-200112070-00010 · Cited by 41
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia
Mocroft, A., Phillips, A. N., Ledergerber, B., Katlama, C., Chiesi, A., Goebel, F.-D., Knysz, B., Antunes, F., Reiss, P., & Lundgren, J. D. (2006) · AIDS · doi:10.1097/01.aids.0000226954.95094.39 · Cited by 41
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens
Lanier, E. R., Givens, N., Stone, C., Griffin, P. C., Gibb, D. M., Walker, A. S., Tisdale, M., Irlbeck, D. M., Underwood, M., Clair, M. S., et al. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00243.x · Cited by 40
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004)
AntonioIribarren, J., Labarga, P., Rubio, R., Berenguer, J., Miró, J., Antela, A., González, J., Moreno, S., Arrizabalaga, J., Chamorro, L., et al. (2004) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(04)73163-8 · Cited by 73
Lamivudine for the treatment of HIV
Kumar, P. N., & Patel, P. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903490418 · Cited by 39
Genetic Association Studies to Detect Adverse Drug Reactions: Abacavir Hypersensitivity as an Example
Hughes, A. R., Brothers, C. H., Mosteller, M., Spreen, W. R., & Burns, D. K. (2009) · Pharmacogenomics · doi:10.2217/14622416.10.2.225 · Cited by 39
Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field
Wittkop, L., Smith, C. J., Fox, Z. V., Sabin, C. A., Richert, L. E., Aboulker, J.-P., Phillips, A. N., Chêne, G., Babiker, A. G., Thiébaut, R., et al. (2010) · Clinical Trials · doi:10.1177/1740774509356117 · Cited by 42
Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.
Hughes, P. J., Cretton-Scott, E., Teague, A., & Wensel, T. M. (2011) · PubMed Central · Cited by 38
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
Keiser, P. H., Sension, M., DeJesus, E., Rodriguez, A. E., Olliffe, J. F., Williams, V. C., Wakeford, J. H., Snidow, J. W., Shachoy‐Clark, A., Fleming, J. W., et al. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-2 · Cited by 38
Liver Enzymes Elevation and Immune Reconstitution Among Treatment-Naïve HIV-Infected Patients Instituting Antiretroviral Therapy
Ofotokun, I., Lennox, J. L., Smithson, S. E., Lu, C., & Easley, K. A. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31811ec780 · Cited by 38
Antiretroviral Treatment Strategies and Immune Reconstitution in Treatment-naive HIV-Infected Patients with Advanced Disease
Soria, A., & Lazzarin, A. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000286598.00313.a6 · Cited by 37
Switching strategies to improve lipid profile and morphologic changes.
Barragán, P., Fisac, C., & Podzamczer, D. (2006) · PubMed · Cited by 37
Discovery of a Novel (+)-γ-Lactamase from Bradyrhizobium japonicum USDA 6 by Rational Genome Mining
Zhu, S., Gong, C., Song, D., Gao, S., & Zheng, G. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01398-12 · Cited by 36
Antiretroviral (ARV) drug resistance in the developing world.
Shekelle, P., Maglione, M., Geotz, M. B., Wagner, G. J., Wang, Z., Hilton, L. G., Carter, J. M., Chen, S. E., Tringle, C., Mojica, W., et al. (2007) · PubMed Central · Cited by 36
Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective
Louie, M. J., & Markowitz, M. H. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00022-0 · Cited by 36
Antiretroviral Recommendations May Influence the Rate of Transmission of Drug‐Resistant HIV Type 1
de Mendoza, C., Rodríguez, C., Bouza, J. M. E., Colomina, J., García, F., Leiva, P. S., Torre‐Cisneros, J., Agüero, J., Pedreira, J. D., Viciana, I., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431203 · Cited by 34

Authors: Staszewski, S.
Affiliations: Goethe University Frankfurt (DE)
Corresponding author: Staszewski, Schlomo
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2001-03-07
Volume: 285
Issue: 9
Pages: 1155
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.285.9.1155
OpenAlex: W2129710521
Cited by: 277
References: 38
Citations by year: 2026: 1 · 2023: 1 · 2022: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 10 · 2012: 6
FWCI: 31.43
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: abacavir, indinavir, lamivudine, zidovudine, HIV infection, antiretroviral-naive patients, triple-drug combination therapy, nucleoside reverse transcriptase inhibitors, protease inhibitors, viral suppression, treatment safety, drug interactions, adverse events, CD4 count, HIV RNA
MeSH terms: Abacavir, Adult, Aged, Double-Blind Method, Drug Resistance, Microbial, Female, Genotype, HIV, Humans, Male, Middle Aged, Mutation, Therapeutic Equivalency, Zidovudine, Dideoxynucleosides, HIV Infections, Survival Analysis, HIV Protease Inhibitors, CD4 Lymphocyte Count, Reverse Transcriptase Inhibitors, Lamivudine, Anti-HIV Agents, Indinavir, Viral Load, Antiretroviral Therapy, Highly Active, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks